je.st
news
MSD Announces First Presentation of Data on the Investigational Use of Pembrolizumab in Patients with Advanced Gastric Cancer at ESMO 2014
2014-09-28 09:15:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Pembrolizumab monotherapy achieved 31 percent overall response rate in patients with PD-L1 positive, advanced gastric cancer Phase 2 study to be initiated in first quarter of 2015 (KEYNOTE-059) WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--MSD, known as Merck in the United States and Canada, today announced the first presentation of data on the investigational use of pembrolizumab the companys anti-PD-1 therapy in PD-L1 positive, advanced gastric cancer. The early findings presented showed an overall response rate (confirmed and unconfirmed) of 31 percent with pembrolizumab as monotherapy, as measured by investigator assessed, RECIST v1.1 (n= 12/39: 95% CI, 17-47). Language: English Contact: For MSDMedia:Ian McConnell, 973-901-5722orClaire Mulhearn, 908-423-7425orInvestors:Joseph Romanelli, 908-423-5185orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: with
data
advanced
presentation
Category:Biotechnology and Pharmaceuticals